Project AIM is a National Initiative to Expand Access to Male Fertility Care
RMA of New York joins Project AIM to serve more Prospective East Coast Parents
GREENWOOD VILLAGE, Colo.–(BUSINESS WIRE)–Posterity Health today announced the launch of Project AIM (Access to care – Inclusion of the Male partner), a nationwide initiative that provides men with at-home testing and access to male fertility specialists. By including the male partner in fertility testing and consultation from the beginning of the process, couples will be able to get pregnant more efficiently.
RMA of New York, widely acknowledged as a national and international leader in state-of-the-art reproductive medicine, is the first to enroll in this telehealth program that is dedicated to diagnosing and treating male fertility issues.
Today, one in eight couples have trouble conceiving, and a male factor may contribute in up to 50% of cases. The male partner is often overlooked, as the focus often begins with the female partner. Posterity Health aims to transform the evaluation of infertility into a “Couples” experience.
Through Project AIM, patients will be able to schedule a semen analysis either at a convenient RMA of New York andrology lab or by using an at-home semen collection kit, and will also have the opportunity to review the results and proceed with a fast-track male fertility consultation. The program is built on the Posterity Health Male Fertility Management Platform, which uses telehealth and at-home testing to facilitate the simultaneous evaluation of “both partners” when a couple is preparing to conceive or experiencing trouble conceiving.
“RMA of New York is committed to providing innovative, comprehensive and accessible fertility care to the community,” said Dr. Natan Bar-Chama, Director of the Center of Male Reproductive Health at RMA of New York. “Project AIM will collaborate with Obstetricians and Gynecologists to offer patients options to conveniently obtain a semen analysis and engage with a novel telehealth platform that will provide them with male infertility expertise. It is gratifying to partake in this joint effort to expedite and facilitate the fertility evaluation of the male.”
Newly released guidelines by ASRM in 2021 highlighted that the fertility workup of couples should begin with the simultaneous evaluation of the male, which includes both a focused reproductive history and a semen analysis.
“Our goal is to work with RMA of New York to change the patient experience and promote the simultaneous evaluation of both partners,” said Pam Pure, co-founder and CEO of Posterity Health. “We want to increase access to expert male fertility care, which will improve efficient diagnosis, treatment and delivery of successful outcomes. In addition, these services provide inclusive family-building resources for the LGBTQ community. Working together, we are confident that we can expedite the time to pregnancy.”
Project AIM’s benefits include:
- Supporting the couple through their journey to parenthood by promoting the coordinated evaluation of both parties
- Exploring the root cause of male infertility and possibly detecting underlying men’s health conditions
- Embracing the LGBTQ community with inclusive family building services
“We know that experiencing infertility can be isolating and overwhelming,” said Pure. “Our goal is to provide Access to Male Fertility Care for every couple trying to conceive, and this will ensure an accelerated and patient-focused path to desired reproductive outcomes.”
About Posterity Health
Posterity Health provides an extensive portfolio of technology-enabled male fertility services, including at-home diagnostics, virtual visits and in-person consults focused on improving a man’s fertility status. The company seeks to educate, engage and treat men, shifting the burden of conceiving from solely the woman and creating a unifying experience for the couple.
Posterity Health is committed to making male fertility management a core part of men’s health.
To learn more, visit www.posterityhealth.com.
About RMA of New York
RMA of New York is widely recognized as a global leader in state-of-the-art reproductive medicine and serves as the division of reproductive endocrinology and infertility at the Icahn School of Medicine at Mount Sinai. Led by an integrated team of physicians and scientists with extensive reproductive endocrinology, infertility, and embryology training, RMA of New York is renowned for its pioneering research in the field and for delivering high IVF success rates. For the past 20 years, the physicians of RMA of New York have consistently been distinguished as top doctors and super doctors by Castle Connolly and New York Magazine. Headquartered in midtown Manhattan, RMA of New York has fertility clinic locations throughout Manhattan, Brooklyn, Westchester, Long Island, and abroad in Mexico City.
Press Release originally published on BusinessWire.